Recruiting × Interventional × Neoplasm Metastasis × Clear all Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
Phase 2 Recruiting
115 enrolled
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
Phase 1/2 Recruiting
231 enrolled
KEYNOTE-E12
Phase 1 Recruiting
78 enrolled
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
442 enrolled
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Phase 1 Recruiting
51 enrolled
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
Phase 2 Recruiting
88 enrolled
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Phase 2 Recruiting
2,900 enrolled
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
Phase 1 Recruiting
43 enrolled
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
Phase 1 Recruiting
66 enrolled
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Phase 1/2 Recruiting
58 enrolled
Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
Phase 1 Recruiting
35 enrolled
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Phase 1 Recruiting
210 enrolled
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
Phase 1 Recruiting
30 enrolled
PROSPER
Phase 1/2 Recruiting
403 enrolled
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers
Phase 1 Recruiting
40 enrolled
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
392 enrolled
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Phase 1 Recruiting
387 enrolled
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Phase 1 Recruiting
36 enrolled
TB06
Phase 3 Recruiting
100 enrolled
TUMS
Phase NA Recruiting
30 enrolled
DUAL-NK-PDAC
Phase 1/2 Recruiting
42 enrolled
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Phase 1 Recruiting
18 enrolled
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
Phase 1 Recruiting
55 enrolled
Keynote B59
Phase 1/2 Recruiting
317 enrolled
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
Phase 2 Recruiting
105 enrolled
Combination Therapy in Cancers With Mutations in DNA Repair Genes
Phase 1 Recruiting
24 enrolled
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Phase 2 Recruiting
45 enrolled
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Phase 1/2 Recruiting
316 enrolled
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
Phase 1 Recruiting
48 enrolled
IDeate-Prostate02
Phase 1/2 Recruiting
360 enrolled
MK-8294-001
Phase 1 Recruiting
67 enrolled
A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
Phase 1 Recruiting
50 enrolled
STRIKE-001
Phase 1 Recruiting
144 enrolled
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
Phase 2 Recruiting
54 enrolled
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/2 Recruiting
300 enrolled
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Phase 1 Recruiting
25 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Phase 1 Recruiting
30 enrolled
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
Phase 1 Recruiting
332 enrolled
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
Phase 2 Recruiting
40 enrolled
SUNRAY-01
Phase 3 Recruiting
1,264 enrolled
68Ga-PSMA PET in the Renal Cell Carcinoma
Phase NA Recruiting
300 enrolled
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
Phase NA Recruiting
10 enrolled
EMPOWER
Phase 1/2 Recruiting
65 enrolled
CyberChallenge
Phase NA Recruiting
190 enrolled
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2 Recruiting
73 enrolled
BRAVESST2
Phase 1/2 Recruiting
150 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Phase 1 Recruiting
110 enrolled
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Phase 1 Recruiting
188 enrolled